Seagen touts PhII da­ta for Ad­cetris/Op­di­vo com­bo; A-Al­pha part­ners with Gilead on HIV

Seagen has re­vealed the da­ta from Part C of a Phase II tri­al eval­u­at­ing Ad­cetris in com­bi­na­tion with Op­di­vo (nivolum­ab), a PD-1 in­hibitor, as well as oth­er chemother­a­py drugs, for a front­line treat­ment for Hodgkin lym­phoma.

Da­ta from 150 pa­tients showed a 95% over­all re­sponse rate and a 93% com­plete re­sponse rate once treat­ment was com­plete. The da­ta for pro­gres­sion-free sur­vival were not avail­able yet. There were no ma­jor ad­verse events, with the most com­mon treat­ment-re­lat­ed side ef­fects be­ing fa­tigue, nau­sea and pe­riph­er­al sen­so­ry neu­ropa­thy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER